{"schema_version":"secwatch.filing_event.v1","accession":"0001559053-23-000031","form_type":"8-K","ticker":"PRTA","cik":"0001559053","company_name":"PROTHENA CORP PUBLIC LTD CO","filed_at":"2023-11-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.508536+00:00","generated_at":"2026-06-09T00:11:50.205359+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Prothena reports Q3 net income of $21.9M; revenue surges to $84.9M on BMS license","bullets":["Net income of $21.9M ($0.38 diluted EPS) vs net loss of $45.8M in Q3 2022; first nine months net loss of $79.6M.","Revenue of $84.9M, primarily from $72.9M collaboration revenue from BMS tau license including $55M option fee.","Cash and restricted cash $673.1M at Sept 30, 2023; guidance for year-end ~$600M.","Upcoming milestones: PRX012 Phase 1 data by year-end 2023; AFFIRM-AL topline in 2024; prasinezumab Phase 2b in 2024.","R&D expenses rose to $57.9M (+45% YoY) due to higher clinical trial costs."],"urls":{"canonical":"https://secwatch.observer/filing/0001559053-23-000031","json":"https://secwatch.observer/filing/0001559053-23-000031.json","markdown":"https://secwatch.observer/filing/0001559053-23-000031.md","text":"https://secwatch.observer/filing/0001559053-23-000031.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1559053/000155905323000031/0001559053-23-000031-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1559053/000155905323000031/prta-20231102.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T00:11:50.205359+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3c9989a2afcd94f43e5aae1803ac7b0989063e23","claim":"PROTHENA CORP PUBLIC LTD CO reported third quarter ended September 30, 2023 results: revenue 84.9 million, net income 21.9 million, EPS 0.38.","evidence_excerpt":"Prothena reported net income of $21.9 million and net loss of $79.6 million , respectively, as compared to a net loss o f $45.8 million and $123.3 million for the third quarter and first nine months of 2022, respectively. Net income per share on a diluted basis for the third quarter was $0.38 and net loss per share for the first nine months of 2023 was $1.50 , a s compared to net loss per share of $0.97 and $2.63 f or the third quarter and first nine months of 2022, respectively. Prothena reported total revenue of $84.9 million and $91.1 million for the third quarter and first nine months of 2023, respectively, as compared to total revenue of $1.5 million and $4.0 million for the third quarter and first nine months of 2022","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1559053/000155905323000031/0001559053-23-000031-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2023"},{"label":"Revenue","value":"84.9 million"},{"label":"Net income","value":"21.9 million"},{"label":"EPS","value":"0.38"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}